Amgen Inc. (NASDAQ:AMGN) cratered 9.8% to $394.56 Tuesday, on track for its worst single-day loss since October 2000.

The damage came from a rival.

Novartis AG (NYSE:NVS) said pelacarsen, its investigational lipoprotein(a) therapy, failed to cut cardiovascular death, heart attacks or strokes versus placebo in a pivotal Phase 3 trial — despite lowering Lp(a) as designed.

ADR shares of Novartis plummeted 14%, on their worst session ever.

Investors immediately marked down Amgen’s olpasiran, which targets the same lipid but uses a different mechanism.

BMO Capital piled on, cutting Amgen to Market Perform. The sell-off spread across biotech, with the iShares Biotechnology ETF (NASDAQ:IBB) down 1.8%.

Image: Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.